22q11.2 Deletion Syndrome Market Set for Growth Through 2034, with the US Leading Demand and 185+ Associated Conditions Shaping Unmet Clinical Needs | DelveInsight

22q11.2 Deletion Syndrome Companies are Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others.
The United States represents the largest 22q11.2 deletion syndrome market compared with EU4, the United Kingdom, and Japan. The disorder is the most common chromosomal microdeletion in humans and is also known as DiGeorge syndrome and velocardiofacial syndrome. It is caused by a missing segment on chromosome 22q11.2, typically occurring as a de novo deletion, though about 10% of cases are inherited.

Associated with more than 185 possible conditions, 22q11.2 deletion syndrome affects multiple organ systems, leading to cardiac defects, developmental and psychiatric disorders, immune dysfunction, and metabolic abnormalities. Diagnosis is challenging due to variable presentation and relies on genetic and imaging techniques such as FISH, MLPA, and chromosomal microarray.

There is currently no cure or approved therapy, and treatment focuses on managing individual symptoms. Despite a limited pipeline, the market is expected to grow due to increased awareness, better uptake of existing supportive treatments, and the potential development of investigational therapies such as Zygel (ZYN002).

DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the 22q11.2 Deletion Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the 22q11.2 Deletion Syndrome Market Report:

* The 22q11.2 Deletion Syndrome market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In October 2024, HARMONY BIOSCIENCES, ZYN-002, expects to begin a pivotal Phase 3 trial for 22q11.2 deletion syndrome (22q) in 2025.
* In 2023, the United States reported the highest number of total prevalent cases of 22q11.2 deletion syndrome across the 7MM.
* In 2023, the EU4 and the UK accounted for approximately 40% of the total prevalent cases of 22q11.2 deletion syndrome in the 7MM.
* In 2023, the majority of 22q11.2 deletion syndrome cases were diagnosed in the 6-12 year age group across the 7MM.
* In 2023, the majority of 22q11.2 deletion syndrome cases were diagnosed in individuals aged 6-12 years across the 7MM.
* Key 22q11.2 Deletion Syndrome Companies: Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others
* Key 22q11.2 Deletion Syndrome Therapies: ZYN002, NB-001, Metyrosine, and others
* The 22q11.2 Deletion Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage 22q11.2 Deletion Syndrome pipeline products will significantly revolutionize the 22q11.2 Deletion Syndrome market dynamics.

22q11.2 Deletion Syndrome Overview

22q11.2 Deletion Syndrome, also known as DiGeorge Syndrome or Velocardiofacial Syndrome, is a genetic disorder caused by the deletion of a small segment on chromosome 22. It affects multiple systems in the body, leading to a wide range of symptoms and clinical presentations.

This syndrome is one of the most common chromosomal microdeletions, occurring in approximately 1 in 4,000 live births. The condition often arises spontaneously (de novo) but can also be inherited in an autosomal dominant pattern.

Key features of 22q11.2 Deletion Syndrome include congenital heart defects (such as tetralogy of Fallot), cleft palate, distinctive facial features, immune deficiencies due to thymus hypoplasia, and hypocalcemia resulting from underdeveloped parathyroid glands. Developmental delays, learning difficulties, and behavioral challenges are also common, with some individuals experiencing psychiatric conditions like anxiety or schizophrenia later in life.

Diagnosis typically involves genetic testing, such as fluorescence in situ hybridization (FISH) or chromosomal microarray analysis. Treatment focuses on managing symptoms and may involve cardiac surgery, speech therapy, calcium supplementation, and immune support.

With early diagnosis and a multidisciplinary care approach, individuals with 22q11.2 Deletion Syndrome can achieve improved quality of life and developmental outcomes.

Get a Free sample for the 22q11.2 Deletion Syndrome Market Report: [https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

22q11.2 Deletion Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

22q11.2 Deletion Syndrome Epidemiology Segmentation:

The 22q11.2 Deletion Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of 22q11.2 Deletion Syndrome
* Prevalent Cases of 22q11.2 Deletion Syndrome by severity
* Gender-specific Prevalence of 22q11.2 Deletion Syndrome
* Diagnosed Cases of Episodic and Chronic 22q11.2 Deletion Syndrome

Download the report to understand which factors are driving 22q11.2 Deletion Syndrome epidemiology trends @ [https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

22q11.2 Deletion Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the 22q11.2 Deletion Syndrome market or expected to get launched during the study period. The analysis covers 22q11.2 Deletion Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the 22q11.2 Deletion Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

22q11.2 Deletion Syndrome Therapies and Key Companies

* ZYN002: Zynerba Pharmaceuticals, Inc.
* NB-001: Nobias Therapeutics, Inc.
* Metyrosine: Bausch Health Americas, Inc.

Discover more about therapies set to grab major 22q11.2 Deletion Syndrome market share @ [https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

22q11.2 Deletion Syndrome Market Strengths

* 22q11.2 deletion syndrome is a rare genetic condition; thus, companies developing treatment options for the same can possess several advantages like 7-year market exclusivity, orphan drug designation, and others.

22q11.2 Deletion Syndrome Market Opportunities

* There exists no approved treatment for the syndrome, as a result, there are several chances for the companies to investigate unmet requirements and develop therapeutic choices that will benefit the patient population and leverage this prevalent orphan indication.

Scope of the 22q11.2 Deletion Syndrome Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key 22q11.2 Deletion Syndrome Companies: Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others
* Key 22q11.2 Deletion Syndrome Therapies: ZYN002, NB-001, Metyrosine, and others
* 22q11.2 Deletion Syndrome Therapeutic Assessment: 22q11.2 Deletion Syndrome current marketed and 22q11.2 Deletion Syndrome emerging therapies
* 22q11.2 Deletion Syndrome Market Dynamics: 22q11.2 Deletion Syndrome market drivers and 22q11.2 Deletion Syndrome market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* 22q11.2 Deletion Syndrome Unmet Needs, KOL's views, Analyst's views, 22q11.2 Deletion Syndrome Market Access and Reimbursement

To know more about 22q11.2 Deletion Syndrome companies working in the treatment market, visit @ [https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. 22q11.2 Deletion Syndrome Market Report Introduction

2. Executive Summary for 22q11.2 Deletion Syndrome

3. SWOT analysis of 22q11.2 Deletion Syndrome

4. 22q11.2 Deletion Syndrome Patient Share (%) Overview at a Glance

5. 22q11.2 Deletion Syndrome Market Overview at a Glance

6. 22q11.2 Deletion Syndrome Disease Background and Overview

7. 22q11.2 Deletion Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of 22q11.2 Deletion Syndrome

9. 22q11.2 Deletion Syndrome Current Treatment and Medical Practices

10. 22q11.2 Deletion Syndrome Unmet Needs

11. 22q11.2 Deletion Syndrome Emerging Therapies

12. 22q11.2 Deletion Syndrome Market Outlook

13. Country-Wise 22q11.2 Deletion Syndrome Market Analysis (2020-2034)

14. 22q11.2 Deletion Syndrome Market Access and Reimbursement of Therapies

15. 22q11.2 Deletion Syndrome Market Drivers

16. 22q11.2 Deletion Syndrome Market Barriers

17. 22q11.2 Deletion Syndrome Appendix

18. 22q11.2 Deletion Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=22q112-deletion-syndrome-market-set-for-growth-through-2034-with-the-us-leading-demand-and-185-associated-conditions-shaping-unmet-clinical-needs-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.